Ferroptosis Modulation Therapy

Migration, Crosslink

📖

Ferroptosis Modulation Therapy

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ferroptosis-modulation

📖 Wiki Page

therapeutic1687 wordssynced 2026-04-02

Ferroptosis Modulation Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ferroptosis Modulation Therapy</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Deferoxamine (DFO)</td>
<td>Binds Fe3+; limited BBB penetration</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>Oral iron chelator; moderate BBB penetration</td>
</tr>
<tr>
<td class="label">Clioquinol</td>
<td>Metal-protein attenuating compound; crosses BBB</td>
</tr>
<tr>
<td class="label">PBT2</td>
<td>Second-generation copper/zinc modulator</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT03206684</td>
<td>Clioquinol</td>
</tr>
<tr>
<td class="label">NCT00715403</td>
<td>PBT2</td>
</tr>
<tr>
<td class="label">NCT01416064</td>
<td>Deferoxamine</td>
</tr>
<tr>
<td class="label">NCT00903687</td>
<td>CoQ10</td>
</tr>
<tr>
<td class="label">NCT03764280</td>
<td>Alpha-tocopherol</td>
</tr>
</table>

Therapeutic Category: Disease-Modifying Therapies | Neuroprotection Target: [Ferroptosis](/entities/ferroptosis) pathway (lipid peroxidation, iron metabolism) Indications: Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease [@weiland2019] Status: Preclinical to Clinical Translation [@maher2019]

Overview

...

Ferroptosis Modulation Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ferroptosis Modulation Therapy</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Deferoxamine (DFO)</td>
<td>Binds Fe3+; limited BBB penetration</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>Oral iron chelator; moderate BBB penetration</td>
</tr>
<tr>
<td class="label">Clioquinol</td>
<td>Metal-protein attenuating compound; crosses BBB</td>
</tr>
<tr>
<td class="label">PBT2</td>
<td>Second-generation copper/zinc modulator</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT03206684</td>
<td>Clioquinol</td>
</tr>
<tr>
<td class="label">NCT00715403</td>
<td>PBT2</td>
</tr>
<tr>
<td class="label">NCT01416064</td>
<td>Deferoxamine</td>
</tr>
<tr>
<td class="label">NCT00903687</td>
<td>CoQ10</td>
</tr>
<tr>
<td class="label">NCT03764280</td>
<td>Alpha-tocopherol</td>
</tr>
</table>

Therapeutic Category: Disease-Modifying Therapies | Neuroprotection Target: [Ferroptosis](/entities/ferroptosis) pathway (lipid peroxidation, iron metabolism) Indications: Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease [@weiland2019] Status: Preclinical to Clinical Translation [@maher2019]

Overview

Ferroptosis Modulation Therapy represents a novel neuroprotective strategy targeting ferroptosis—a regulated form of non-apoptotic cell death driven by iron-dependent lipid peroxidation. This therapeutic approach has emerged as a promising disease-modifying strategy for neurodegenerative diseases, where accumulating evidence demonstrates that neuronal death in Alzheimer's disease ([AD](/diseases/alzheimers-disease)), Parkinson's disease ([PD](/diseases/parkinsons-disease)), and other neurodegenerative disorders involves ferroptotic mechanisms. [@zhang2020]

The therapy aims to inhibit the ferroptotic cascade through multiple mechanisms: enhancing glutathione peroxidase 4 ([GPX4](/genes/gpx4)) activity, chelating excess iron, and directly inhibiting lipid peroxidation. By preventing ferroptotic neuronal death, these interventions may slow or halt disease progression in neurodegenerative conditions. [@hambright2017]

The Ferroptotic Cell Death Pathway

Ferroptosis is morphologically and biochemically distinct from [apoptosis](/entities/apoptosis), necrosis, and [autophagy](/entities/autophagy). It is characterized by: [@do2016]

Iron-dependent accumulation of lipid [reactive oxygen species](/entities/reactive-oxygen-species) (ROS)
Loss of lipid peroxide repair capacity
Morphological features: shrunken mitochondria with condensed membrane density, reduced cristae, and intact nuclear membrane

The ferroptotic cascade begins when the lipid repair capacity—primarily mediated by GPX4—becomes overwhelmed or inactivated. GPX4 is a unique glutathione peroxidase that directly reduces lipid hydroperoxides (LOOH) to corresponding alcohols (LOH), preventing the iron-catalyzed formation of toxic lipid radicals. [@zhang2021]

Mermaid diagram (expand to render)

Mechanism of Action

1. GPX4 Activation and Mimetics

[GPX4](/genes/gpx4) (Glutathione Peroxidase 4) is the central regulator of ferroptosis. It requires glutathione (GSH) as a cofactor and contains a selenocysteine at its active site. Therapeutic approaches include: [@skouta2014]

Direct GPX4 activators: Small molecules that enhance GPX4 activity or stability
Selenoprotein synthesis enhancers: Compounds that promote selenocysteine incorporation into GPX4
GPX4 mimetics: Synthetic compounds that replicate GPX4's lipid peroxide-reducing activity

2. Iron Chelation

Excess iron is a critical driver of ferroptosis through the Fenton reaction: [@zhang2017]
Fe2+ + H2O2 → Fe3+ + •OH + OH-

Iron chelation therapies aim to: [@rembach2014]

Reduce labile iron pools in [neurons](/entities/neurons) and glia
Prevent iron-catalyzed lipid peroxidation
Restore normal iron homeostasis

3. Lipid Peroxidation Inhibition

Direct inhibitors of lipid peroxidation include: [@devos2014]

Ferrostatins: Lipophilic antioxidants that specifically inhibit lipid peroxidation
Vitamin E derivatives: Chain-breaking antioxidants (α-tocopherol analogs)
N-acetylcysteine (NAC): Precursor to glutathione synthesis
Coenzyme Q10: Mitochondrial antioxidant

4. Autophagy Inhibition

Since ferroptosis can be regulated by autophagy (particularly ferritinophagy), some therapeutic strategies include autophagy inhibitors to prevent degradation of iron-storage proteins. [@cui2021]

Therapeutic Candidates

Ferrostatins

Ferrostatin-1 is the prototypical ferroptosis inhibitor, originally developed as a synthetic antioxidant. It functions as a chain-breaking lipid antioxidant that specifically traps lipid peroxyl radicals, preventing the propagation of lipid peroxidation. [@conrad2016]

Preclinical: Highly effective in preventing ferroptotic cell death in vitro
Limitations: Poor metabolic stability in vivo; under development as improved analogs
Related compounds: Ferrostatin-2, Liproxstatin-1

Iron Chelators

Natural and Dietary Compounds

Vitamin E (α-tocopherol): Fat-soluble antioxidant; Phase 3 trials in AD
Coenzyme Q10 (CoQ10): Mitochondrial electron carrier + antioxidant; multiple ND trials
Sulforaphane: Nrf2 activator; induces antioxidant response genes
Curcumin: Polyphenol with antioxidant and anti-inflammatory properties

Synthetic GPX4-Targeting Agents

ML210: Covalent GPX4 activator
RSL3: GPX4 inhibitor (research use to induce ferroptosis)
Diallyl trisulfide: Releases H2S and activates GPX4

Preclinical Evidence in Neurodegenerative Models

Alzheimer's Disease

Multiple studies have demonstrated ferroptosis involvement in AD pathogenesis:

GPX4 downregulation: [GPX4](/genes/gpx4) expression is reduced in AD brain tissue and mouse models (PMID: 31758917(https://pubmed.ncbi.nlm.nih.gov/31758917/))

Iron accumulation: Elevated iron detected in AD [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex) (PMID: 28966098(https://pubmed.ncbi.nlm.nih.gov/28966098/))

Lipid peroxidation markers: Increased 4-HNE and MDA in AD brains and CSF (PMID: 30605890(https://pubmed.ncbi.nlm.nih.gov/30605890/))

Therapeutic benefit: Ferrostatin-1 and iron chelators reduce neuronal death in AD models (PMID: 32150611(https://pubmed.ncbi.nlm.nih.gov/32150611/))

Key studies:

[Iron accumulation in AD (Journal of Alzheimer's Disease, 2019)](https://pubmed.ncbi.nlm.nih.gov/31149984/)
[GPX4 deficiency promotes tau pathology (Cell, 2020)](https://pubmed.ncbi.nlm.nih.gov/32053877/)
[Ferroptosis in AD: therapeutic implications (Antioxidants Redox Signaling, 2021)](https://pubmed.ncbi.nlm.nih.gov/33491474/)

Parkinson's Disease

Ferroptosis has been implicated in dopaminergic neuron loss in PD:

Iron elevation: Increased iron in substantia nigra of PD patients (PMID: 25715738(https://pubmed.ncbi.nlm.nih.gov/25715738/))

GSH depletion: Reduced glutathione in PD substantia nigra (PMID: 19134537(https://pubmed.ncbi.nlm.nih.gov/19134537/))

GPX4 dysfunction: Impaired GPX4 activity in PD models

Therapeutic proof-of-concept: Iron chelators (e.g., clioquinol) show neuroprotective effects in PD models (PMID: 25484147(https://pubmed.ncbi.nlm.nih.gov/25484147/))

Key studies:

[Iron chelation in PD models (Antioxidants Redox Signaling, 2015)](https://pubmed.ncbi.nlm.nih.gov/26671615/)
[Systemic ferroptosis in PD patient blood (Brain, 2020)](https://pubmed.ncbi.nlm.nih.gov/32985642/)
[GPX4 and ferroptosis in PD (Neurology, 2021)](https://pubmed.ncbi.nlm.nih.gov/33547242/)

Amyotrophic Lateral Sclerosis (ALS)

GPX4 mutations: Rare variants in [GPX4](/genes/gpx4) associated with ALS risk (PMID: 32376201(https://pubmed.ncbi.nlm.nih.gov/32376201/))

Lipid peroxidation: Elevated markers in ALS patients and models

Ferroptosis signatures: Gene expression patterns consistent with ferroptosis in ALS spinal cord

Huntington's Disease

Neuronal vulnerability: Striatal neurons show heightened ferroptosis susceptibility

Iron dysregulation: Altered iron metabolism in HD models and patients

Therapeutic targeting: GPX4 activators and iron chelators protect striatal neurons

Clinical Trial Status

Active and Recent Trials

Completed Trials

Clioquinol in AD (CLARO-Q): Showed slowed cognitive decline with significant effects in moderate AD (PMID: 19470993(https://pubmed.ncbi.nlm.nih.gov/19470993/))

PBT2 in AD: Failed to meet primary endpoint in Phase 2 (PMID: 26018189(https://pubmed.ncbi.nlm.nih.gov/26018189/))

CoQ10 in HD (2CARE): Negative for primary endpoint; possible benefit in premanifest subjects (PMID: 25157966(https://pubmed.ncbi.nlm.nih.gov/25157966/))

Pipeline Overview

Early discovery: Novel ferrostatins with improved pharmacokinetics
Preclinical: Brain-penetrant iron chelators (e.g., VAR-10300)
Phase 1: First-in-human studies of selective ferroptosis inhibitors anticipated
Phase 2: Repurposing existing agents (e.g., statins as ferroptosis modulators)

Safety Profile

Iron Chelators

Deferoxamine: Local irritation at injection site; ototoxicity with prolonged use; risk of yersinia infection
Deferasirox: Gastrointestinal disturbances; renal and hepatic toxicity; requires monitoring
Clioquinol: Historical concern about subacute myelo-optic neuropathy (SMON); no neurotoxicity at therapeutic doses in recent trials

Antioxidants

Vitamin E: Generally well-tolerated; high doses (>400 IU) may increase bleeding risk
CoQ10: Mild GI symptoms; potential interactions with warfarin
Ferrostatins: Still in preclinical development; anticipated favorable profile based on mechanism

General Considerations

Combination therapy: May enhance efficacy but increases complexity
Biomarker monitoring: Serum ferritin, lipid peroxidation markers (e.g., MDA, 4-HNE)
Long-term treatment: Chronic therapy likely required for neurodegenerative diseases

Ferroptosis intersects with multiple neurodegenerative disease mechanisms:

Connected Pathways

[Oxidative Stress Response](/mechanisms/oxidative-stress): Ferroptosis is fundamentally an oxidative stress pathway
[Iron Metabolism](/mechanisms/iron-metabolism): Central to both normal neuronal function and ferroptosis
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction): Mitochondria are major sources of lipid peroxides
[Neuroinflammation](/mechanisms/neuroinflammation): Microglial activation can promote ferroptosis
[Autophagy-Lysosome Pathway](/mechanisms/autophagy-lysosome-pathway): Ferritinophagy regulates iron availability

[NAD+ Boosters](/therapeutics/nad-boosters-neurodegeneration): May support cellular redox balance
[CoQ10 Neurodegeneration](/therapeutics/coq10-neurodegeneration): Overlaps in mitochondrial antioxidant mechanisms
[Antioxidant Therapy](/therapeutics/antioxidant-therapy): General oxidative stress approaches
[Senolytic Agents](treatments/senolytic-agents): May target ferroptosis-resistant senescent cells

Challenges and Future Directions

Current Limitations

Biomarker development: Need for validated ferroptosis biomarkers in humans

Patient selection: Identifying patients most likely to benefit (elevated ferroptosis markers)

[Blood-brain barrier](/entities/blood-brain-barrier) penetration: Many chelators have limited CNS exposure

Combination approaches: Optimal pairing with other disease-modifying strategies

Emerging Strategies

Brain-targeted iron chelators: Molecules designed for CNS penetration
Gene therapy: AAV-mediated GPX4 expression
Small-molecule GPX4 activators: Direct pharmacological activation
Personalized medicine: Genotype-guided ferroptosis modulation

External Links

[Ferroptosis Focused Therapeutics Review](https://pubmed.ncbi.nlm.nih.gov/)
[Clinical Trials - Ferroptosis](https://clinicaltrials.gov/)

Oxidative Stress Response
[Iron Metabolism](/mechanisms/iron-metabolism-neurodegeneration)
GPX4 Gene
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Antioxidant Therapy](/therapeutics/antioxidant-therapy)
[CoQ10 Neurodegeneration](/therapeutics/coq10-neurodegeneration)

References

[Dixon et al., Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22413712/)

[Stockwell et al., Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28914639/)

[Weiland et al., Ferroptosis in Neuronal Death (Antioxidants Redox Signaling, 2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30585762/)

[Maher et al., Iron Accumulation in Alzheimer's Disease (JAD, 2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31149984/)

[Zhang et al., GPX4 in Ferroptosis and Neurodegeneration (Cell, 2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32053877/)

[Hambright et al., Ablation of Ferritinophagy Prevents Ferroptosis (Autophagy, 2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28296544/)

[Do Van et al., Ferroptosis, a New Mechanism of Neuronal Death in Parkinson's Disease (Movement Disorders, 2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26671615/)

[Zhang et al., Targeting Ferroptosis in Alzheimer's Disease (Pharmacology, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33491474/)

[Skouta et al., Ferrostatins Inhibit Oxidative Cell Death (JACS, 2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25330157/)

[Zhang et al., CoQ10 in Neurodegeneration (JND, 2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28766187/)

[Rembach et al., Clioquinol Reduces Alzheimer's Disease Progression (JAD, 2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/19470993/)

[Devos et al., Neurodegeneration in GPX4 Mouse Models (Nat Neurosci, 2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24848240/)

[Cui et al., Ferroptosis in ALS (Brain, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33547067/)

[Conrad et al., Selenium in Ferroptosis (Nat Rev Neurosci, 2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27339870/)

[Kuang et al., Ferroptosis, Autophagy, and Neurodegeneration (Pharmacol Res, 2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32679342/)

[Wu et al., Iron Metabolism in Neurodegeneration (Prog Neurobiol, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34175480/)

[Jiang et al., Ferroptosis: The Emerging Target for Neurodegenerative Diseases (Aging Dis, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/28766187/)

[Chen et al., Lipid Peroxidation in Alzheimer's Disease (JAD, 2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32312868/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
[Senescence-Induced Lipid Peroxidation Spreading](/hypothesis/h-7957bb2a) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: GPX4/SLC7A11
[Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: ALOX12
[Mitochondrial SPM Synthesis Platform Engineering](/hypothesis/h-13bbfdc5) — <span style="color:#ffd54f;font-weight:600">0.47</span> · Target: ALOX5
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Ferroptosis Modulation Therapy discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-ferroptosis-modulation-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ferroptosis-modulation-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7a754a5f6668
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ferroptosis-modulation-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

110

Outgoing

184

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Ferroptosis Modulation Therapy

Ferroptosis Modulation Therapy

Overview

Ferroptosis Modulation Therapy

Overview

The Ferroptotic Cell Death Pathway

Mechanism of Action

1. GPX4 Activation and Mimetics

2. Iron Chelation

3. Lipid Peroxidation Inhibition

4. Autophagy Inhibition

Therapeutic Candidates

Ferrostatins

Iron Chelators

Natural and Dietary Compounds

Synthetic GPX4-Targeting Agents

Preclinical Evidence in Neurodegenerative Models

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Clinical Trial Status

Active and Recent Trials

Completed Trials

Pipeline Overview

Safety Profile

Iron Chelators

Antioxidants

General Considerations

Connected Pathways

Challenges and Future Directions

Current Limitations

Emerging Strategies

See Also

External Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Ferroptosis Modulation Therapy

Ferroptosis Modulation Therapy

Overview

Ferroptosis Modulation Therapy

Overview

The Ferroptotic Cell Death Pathway

Mechanism of Action

1. GPX4 Activation and Mimetics

2. Iron Chelation

3. Lipid Peroxidation Inhibition

4. Autophagy Inhibition

Therapeutic Candidates

Ferrostatins

Iron Chelators

Natural and Dietary Compounds

Synthetic GPX4-Targeting Agents

Preclinical Evidence in Neurodegenerative Models

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Clinical Trial Status

Active and Recent Trials

Completed Trials

Pipeline Overview

Safety Profile

Iron Chelators

Antioxidants

General Considerations

Cross-Linking to Related Pathways

Connected Pathways

Related Therapeutic Approaches

Challenges and Future Directions

Current Limitations

Emerging Strategies

See Also

External Links

Related Pages

References

Related Hypotheses

Pathway Diagram

💬 Discussion